DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its ...
If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...
Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results